The number of pediatric and young adult cancer survivors is increasing globally due to earlier diagnostics and expansion of targeted chemo-and biological-based therapeutics. As a consequence, cancer-related infertility and reproductive hormone loss is of increasing concern for both male and female survivors. We attempted to estimate the reproductive loss in oncofertility-practicing countries and to develop a global oncofertility index (OFI). This would allow an accounting of the level of urgency of the issue and would provide national comparisons of fertility loss, which differ based on the prevalence and/or diagnosis frequency and treatment variables by countries or region. While the goal is laudable, an index such as this is unachievable due to the lack of the kind of information that would be necessary to calculate such a meaningful index. Without this metric, we will be unable to assess how oncofertility concerns are being addressed and what lessons can be learned from countries that improve such an index over time.
Background
Cancer continues to be a matter of great public health concern around the globe [1] , with 14 million new cancer cases diagnosed in 2012. Although many people associate cancer with aging, approximately 15% of patients diagnosed with cancer are younger than 45 years [1, 2] . Survival rates are increasing due to early diagnostics, the development of new drug strategies, and more personalized treatment plans based on risk factors and genomic data [1] [2] [3] [4] . Late effects of cancer and its treatment are, therefore, taking on new urgency. For example, off-target effects of female cancer treatment on the gonads may result in ovarian damage or failure, early menopause, and/or genetic damage to growing eggs in female patients [5] and a decrease 1124 C The Authors 2017. Published by Oxford University Press on behalf of Society for the Study of Reproduction. All rights reserved.
For permissions, please e-mail: journals.permissions@oup.com in the quality and production of sperm in male patients [6, 7] . Thus, female and male survivors are more likely than their siblings to be rendered infertile [2, 6] . Moreover, as a result of early menopause and estrogen deficiency [8] , female patients may develop other iatrogenic conditions, such as fatigue, delayed puberty, hypogonadism, osteoporosis, and cardiovascular disease. Many studies have shown that infertility following cancer treatment is a major concern to cancer survivors [9] . Potential and actual infertility affect the future quality-of-life of patients and will likely lead to psychological distress; for this reason, infertility is a predictor of stress in present and future relationships [9] [10] [11] . Since by 2020, 1:750 U.S. adults will have survived childhood cancer, the reproductive health of cancer survivors drive a broad public health agenda for prevention, follow up, and psychological support [12] . Our group attempted to define the burden of global reproductive loss incidence for cancer patients in the AYA (adolescent young adult) population at initial diagnosis. Oncofertility is a term that describes this field, therefore, we calculate a global and national oncofertility index (OFI) defined as the number of individuals per 100 000 in a given year within a specified region or country whose reproductive health is at risk due to cancer diagnosis/gonadotoxic treatment. The Human Development Index (HDI) as defined by the United Nations Development Programme is the assessment of the development level of a country in terms of average education levels, years of schooling and levels of education, and standard of living [13] . The HDI was used to determine the relationship between the calculated OFI and the development level of a country. While a report on the global scope of this emerging concern and the geographic impact that cancer and its treatment has on patients of reproductive age is of great interest, gaps in our field limit our ability to address this problem. Here we denote the major hurdles and that which is lost if we are unable to develop this sort of metric.
Weighting of age with family desire across the adolescent young adult spectrum What the issue is While oncofertility options have expanded globally, there still exists a need to identify the specific fertility threats associated with disease diagnosis and treatment patterns by country. Therefore, we have attempted to develop an OFI that takes into account the incidence of cancers that affect this AYA population (15-39 years old). The inclusion age for AYA is defined differently around the globewe use the U.S. data of 15-39, in part, because it represents the time of maximal female fertility/time when mature fertility interventions exist that have a high probability of positive outcomes. We included the entire reproductive age range of 15-39 [1] for both male and female, although males and females may experience different treatments and/or effects of cancer on fertility. It is acknowledged that males can often bank sperm at older ages than females may be able to bank high-quality gametes. Differences in family desire may vary by age, as well. For example, a 16-year-old having been rendered infertile will be weighted the same as a 35-year-old, despite the fact that the latter may already have had one or more children and is likely to feel and think differently about infertility. Cancer patients may have other reasons for infertility before or after cancer treatment such as gynecological conditions or sexually transmitted infections, which would not be included in the OFI but is an important part of the patient risk profile. Furthermore, it is desired to include prepubertal children and children transitioning through puberty in the estimate, as well, but these groups are afflicted by different cancers, and these cancers even differ by country [1] . Furthermore, Centers for disease control and prevention data [14] show that the average age that women have their first child remains at 30 years in Europe, Australia, and Japan. The U.S. reports a lower average age (26 years old), and this varies by ethnicity. Data on pregnancy rates of women in developing countries between the ages of 39 and 40 are not available. Where women may be reproductively active at ages older than 39, (1) the competence of banked eggs or tissues will be low, (2) the likelihood of the treatment impacting the ovarian reserve is high, and (3) the ability of patients to utilize assisted reproductive technologies following recovery (a minimum of 3 years) limits the impact of assisted interventions. Additionally, cultural and religious differences will result in varying ages that individuals begin families and that patients feel their family is completed, which would have an effect on the OFI values per country. Unfortunately, such specific data does not exist, as of now. In future years, when more thorough data are made available by tracking fertility outcomes after cancer treatment, there may be a way to develop a strategy that attempts to integrate age with family desire across the AYA spectrum.
What we did
We matched the age group for the male and female sexes for three reasons: (1) this range provides parity in reporting an OFI for both sexes, (2) this range represents the time of maximal family building globally, and (3) this age restriction provides methodological equivalence for the OFI.
We argue that there is benefit to deriving a global value that establishes a baseline for fertility concerns which can (1) be monitored over time, (2) be used across different geographies, (3) be modified for specific regions, and (4) be tailored to individuals. It is vital that the field have some common notion of the issues associated with fertility management in the cancer setting, and this index is a starting point for a field that to-date has not had any rigorous assessment of the overall problem. Because of including only the AYA population in future analyses, a small number of patients who have not yet completed their family in this age group may be missed, but those numbers will be quite low.
Why this is inadequate
The majority of cancer diagnoses occurring within this statistic are not evenly distributed evenly across this age range. Fifteen percent of patients included pediatric cancers (ages 0-15), but the majority of cancer actually occurred between ages 40-45. That leaves a small, rather unspecified group between the ages of 15-39. The authors cannot control or account for the need to weight variables such as "completed family"; "no desire for children"; and varying treatment in the same tumor types due to the stratification of treatment based on risk and treatment with modalities that have limited or no animal or human data, such as immunotherapy.
What can be done
To reach a more reliable OFI, age of family desire should be taken into account and added to the formula. As we know that this age varies across the globe, we also know that this age is higher in cancer survivors than in healthy young people [14] . We must gather information about this age to adjust OFI calculations.
Calculators of risk of infertility What the issue is
The key issue here is the accuracy of the risk of loss-of-fertility in relation to the various diagnoses. One important consideration is that there is limited access to tools that provide such information.
LIVESTRONG/ American Society of Clinical Oncology (ASCO) has fertility risk calculators that describe risk of amenorrhea rather than of infertility in women, and in men, the risk is stated in terms of risk of permanent or temporary azoospermia. Furthermore, many of the risks are stratified by age in the calculators; for example, the low-risk therapies for breast cancer are specified only to be relevant to women under the age of 30.
Despite the value of comparing oncofertility risks by country, there are issues associated with the development and deployment of an OFI. First, the LIVESTRONG/ASCO fertility risk calculator is the basis for estimates of fertility loss. The fertility risk calculator reports wide ranges of fertility risks; for example, the intermediate risk range is 30%-70%, which poses significant difficulties for clinicians making recommendations for treatment. Although this is the best tool available for assessing risk to-date, it also requires continual development and stratification. The OFI calculated assumes that all patients have access to any and all necessary treatments. Moreover, the fertility risk calculators do not include updates to treatment protocols and the more recently deployed immunotherapy or combined chemotherapy immunotherapy treatments [15] .
We used datasets that are the gold standard in the world, and while there may be underreporting, it seems logical to establish the current risk of infertility with what we currently have available and to refine with time. We have not considered the risks of relapse, further treatment, secondary cancers, and the use of Assisted reproductive technology (ART), which may occur in future years. Also, access to ART will not change the OFI values. Including hematopoietic stem cell transplantation (HSCT) treatment for nonmalignant diseases is worth considering in future years, as well. The OFI is the first estimate of its kind, and we expect it to not only be a valuable snapshot, but to also be integrated into a longitudinal description of the fertility threats that are experienced by specific regions of the world. It could also be used to look at the changes in reproductive risk with new treatments.
What we did
There are differences in the way ASCO and other cancer organizations describe the risk. This highlights the difficulty that physicians have in providing information about risk of infertility or azoospermia. We also acknowledge the issues associated with age. While these are considerations, we have used the best available data to provide an index. In future years, individual cancers could be evaluated, specifically.
For now, the most accurate estimates of incidence and mortality rates by cancer site and sex divided into age groups for 184 countries can be obtained from the GLOBOCAN 2012 dataset, developed by the International Agency for Research on Cancer (IARC) [16] . The estimates are based on the most recent data available from IARC. GLOBOCAN used a total of nine methods for the estimation of incidence and mortality rates. These methods were assessed by Antoni et al. to confirm the quality of the dataset's nine methods to predict recent cancer incidences [17] . Therefore, the dataset can be used to determine the top ten incidences and mortality rates for both male and female cancer patients of reproductive age (15-39) per cancer type. Since LIVESTRONG (former Fertile Hope)/ASCO have fertility risk charts for both the male and female sexes [18] [19] [20] and are used as the gold standard in the world, these charts could be used to determine the infertility risk ratio (IFRR) per cancer type. The LIVE-STRONG/ASCO charts contain scaled categories to describe the risk level of each cancer type due to accepted treatments, namely high risk (prolonged/permanent azoospermia: >70% chance to develop amenorrhea), intermediate risk (occurrence of prolonged/permanent azoospermia: 30%-70% chance to develop amenorrhea), lower risk (temporary damage to sperm production: <30% chance to develop amenorrhea), very low/no risk (temporary damage to sperm production: <30% chance to develop amenorrhea), and unknown risk (negligible to no effect). To produce a mean risk, the categories could be given a weight from 0-4; 0 for the unknown/negligible risk group, since there are no conclusive data yet regarding the reproductive effects of drugs placed in this category used to treat the cancer types listed; 1 for the very low/no risk group; 2 for the cancer types listed in the low risk group; 3 for the cancer types listed in the intermediate risk group; and 4 for the cancer types listed in the high risk group. In the end, the value was divided by 4 to deduce the mean risk. Essentially, with this method, a cancer type listed in only one category, for example cervical cancer, which resides in the intermediate risk category (weight 3), would be considered 3/4 = 0.75 or 75% risk. For cancers mentioned more than once in the table (due to different treatments given at different stages for the same cancer type), a weighted average could be calculated. Then, the IFRR could be multiplied by the incidence rate of the respective cancer type in each region where it was listed in the top ten in order to determine the OFI for that cancer type and the cumulative OFI per country (after adding all of the top ten OFIs in each country). Finally, a cumulative "global" OFI, incidence, and mortality could be calculated by adding all those numbers per cancer type in the included oncofertility-practicing countries for male and female sexes. Cancer types not mentioned in LIVESTRONG's chart would not be included in the study, and cancers that were only mentioned in the unknown/negligible risk group would be assigned a zero risk.
Why this is inadequate
Unfortunately, despite our attempts to create an OFI the data available are limited, which hinders our ability to calculate an accurate OFI estimation:
1. We used the LIVESTRONG risk calculator to determine the risk to fertility caused by treatment, however, the data used to create the LIVESTRONG risk calculator are limited and describe the risk of amenorrhea in females and the risk of permanent or temporary azoospermia in males, which cannot be considered to be equal to the risk of infertility [20] [21] [22] . There is a lack of validated international data on the risk of loss of fertility in relation to the various cancer diagnoses. 2. The LIVESTRONG risk calculator is out of date in 2017, focuses on protocols from only America and Europe, and does not have a full list of treatment protocols for each tumor group currently available from other clinical trial groups, e.g. National Comprehensive Cancer Clinical Network or National Cancer Institute. The LIVESTRONG risk calculator also does not include newer treatment regimens that use immunotherapy in combination or on their own. 3. We made an assumption that the same tumor types are treated in the same way worldwide using the protocols available on the LIVESTRONG risk calculator. The lack of treatment information from each country and the lack of international protocols on the LIVESTRONG risk calculator make a more accurate assessment of OFI impossible.
Our OFI was developed assuming that the risk of infertility is the same in pediatric, adolescent, and young adult patients of reproductive age without considering the differing impact of age at treatment on a patient's future fertility. What can be done An update of the Livestrong-ASCO risk calculator utilized in this study is recommended for new cancer treatment modalities, worldwide cancer treatment protocols, and to be stratified for age of treatment. This would optimize the OFI's reliability. Cancer treatment rather than cancer type is the most important driver to the equation and harmonization of cancer care and is not currently on the global oncology agenda.
Cancer treatment and not type is the most important driver to the equation that is heterogeneous What the issue is
The context of infertility and cancer is really about the cancer treatment and less about the cancer itself. Although some cancers, such as testicular cancer, Hodgkin's lymphoma, or ovarian cancer, may, in fact, cause infertility, these are still a minority of cancers. Also, treatment protocols and even accessibility to treatments might differ between all the HDI countries. Unfortunately, most aggregated data that can be evaluated are data on cancers and not treatments.
Furthermore, treatments, such as HSCT, are commonly used in many hematological cancers or in secondary cancers, and carry near certain risks of infertility. Since there are no conclusive data available, it could be suggested to only asses the risk of infertility with the initial diagnosis and not consider the risk of relapse and further treatment or the risk of secondary cancers because of its complexity.
Additionally, in some developing countries, patients will not have access to all components of cancer treatment. However, as of now, it is impossible to determine which countries have access to every component of cancer treatment, as this will vary within countries and will be based on individual wealth and other factors.
What we did
The range of fertility risk is a field-wide problem, since we still do not have accurate tools to assess individual fertility at the time of diagnosis nor the specific effects of a drug on gamete health in males and females. As the field continues to develop, new strategies for better "personalizing" cancer treatment measures and fertility risk measures will be developed, and our OFI can then be updated. The OFI we attempt to create could be a starting point for a newly emerging field. This is an area of intense research around the globe, thus, as more precision is brought to the currently approved drug treatments, more tailored risk estimates will be developed, which can then be plugged into the OFI equations.
Why this is inadequate
With the exception of cancers in the neuroendocrine axis or cancer of gonadal organs, it is the treatment that patients receive and not the original cancer that influences the individual cancer patients' chance of infertility. However, additional factors such as cytogenetics, immunophenotyping, and response to treatment are all factors that allow us to stratify cancer survival risk and change treatment not considered by other methodology. New novel chemotherapy and immunotherapy drugs in combination or individually has resulted in treatment protocols that do not have animal or human data on the gonadotoxic risk, and the fertility risk calculator has, therefore, not included any available data in this area resulting in inaccuracies in the OFI [23] .
What can be done
Since cancer treatment is the most important driver to the OFI calculation, ideally, the starting point of the Livestrong/ASCO risk calculator should be cancer treatment instead of cancer type. Within this field, data of large cohort studies on fertility after cancer treatment in the AYA survivors are essential and should be collected.
Conclusions
In short, while fertility management in the cancer setting is emerging as an important issue for patients and providers, we lack quantitative metrics to assess the global burden of infertility or sterility in the cancer setting. A metric of this kind would permit experts to determine the scale of the problem and to identify global hot or cool spots where best practices exist and where inadequate options are provided, respectively. This would enable more educational tools to be created, accounting for regional, country, or state-based issues, as well as cultural differences that accelerate or limit reproductive technologies. The most important existential threat is that in the absence of a leveling of the playing field, the driver to access will be wealth. Knowing where the gaps are, we hope that scientists, clinicians, and policy makers can work to lessen the likelihood that oncofertility methods contribute to a widening gap in healthcare services.
Finally, this exercise points out how important but how difficult field-spanning concepts like oncofertility are. The work done by bench scientists to create new fertility options is only valuable if they can be delivered to the right patients under the right care plan. Future studies will attempt to bring together thought leaders on each of the action plans that are outlined above with the overall goal of improving the landscape of care for patients facing life-preserving but fertility-threatening cancer treatments around the globe.
